RxDoctor Payments Data

Syed Rehman, MD

Internal Medicine · Richmond, VANPI 1205827615

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $43,875 of the $48,759 with a category attached, or 90.0%. Shire North American Group Inc accounts for 81.6% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2019 at $39,828 and has fallen 99.7% since, to $120 in 2025. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$48,759in general payments, 2019–2025

Across 64 payments — averaging $761.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shire North American Group Inc$40K
  • Takeda Pharmaceuticals U.S.A., Inc.$8K
  • Bard Peripheral Vascular, Inc.$923
  • Medtronic$144
  • AstraZeneca$30
  • Cordis US CORP.$23
  • plus $27 from 2 others

What the payments were for

  • Speaking & faculty fees$43,87590%
  • Travel & lodging$3,6487%
  • Food & beverage$1,2363%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,759 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$86,284
Medicare patients
171
Services billed
325

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban178$99,250
XareltoRivaroxaban45$26,032
EntrestoSacubitril/Valsartan23$14,605
GemtesaVibegron14$6,676
MyrbetriqMirabegron11$5,365
Memantine Hcl ErMemantine Hcl17$4,647
Atorvastatin Calcium242$3,738
Rosuvastatin Calcium62$2,908
Pantoprazole Sodium195$2,891
Levothyroxine Sodium221$2,882
Metoprolol Succinate164$2,761
Bumetanide77$2,492
Memantine Hcl73$2,446
Amlodipine Besylate234$2,113
Hydroxychloroquine Sulfate11$1,984

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$11$26,03245 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →